Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

Pushko, Peter; Tumpey, Terrence M.; Hoeven, Neal Van; Belser, Jessica A.; Robinson, Robin A.; Nathan, Margret; Smith, Gale; Wright, Daniel; Bright, Rick A.

doi:10.1016/j.vaccine.2007.02.059

Cited by 89 publications

(60 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposome-antigen complexes could induce significantly higher cellular immune responses that antigen carried by aluminum hydroxide after subcutaneous administration in mice [174]. Other additives, such as vitamine E, can be included to improve the adjuvant ef-fect (novasomes) [175].…”

Section: Liposomes/proteoliposome/virosomesmentioning

confidence: 99%

“…Virus-like particles (VLPs) has been widely used for vaccination against the corresponding virus such as influenza virus [175,258]. VLPs possess key immunologic features of viruses-repetitive surfaces, particulate structures and induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors.…”

Section: Virus-like Particles (Vlps)mentioning

confidence: 99%

See 1 more Smart Citation

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

Section: Liposomes/proteoliposome/virosomesmentioning

confidence: 99%

Section: Virus-like Particles (Vlps)mentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…VLP vaccines for viruses such as hepatitis B virus and human papillomavirus are safe for broad and repeated application [4][5][6]. In recent studies, immunization of mice with monovalent influenza VLPs reduced challenge virus replication and conferred protection against relatively low doses of viral challenges [7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…Previous studies demonstrated that monovalent influenza VLPs could be a promising alternative influenza vaccine [7][8][9][10][11]. However, the immune responses to multivalent influenza VLP vaccine have not been investigated despite its critical significance in evaluating the alternative influenza vaccine.…”

Section: Introductionmentioning

confidence: 99%

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

Quan

Steinhauer

Huang

et al. 2008

Vaccine

View full text Add to dashboard Cite

The conventional egg-grown influenza vaccines are trivalent. To test the feasibility of using multivalent influenza virus-like particles (VLPs) as an alternative influenza vaccine, we developed cell-derived influenza VLPs containing the hemagglutinin (HA) of the H1 subtype virus A/PR/ 8/34 or the H3 subtype virus A/Aichi/2/68. Mice immunized intramuscularly with bivalent influenza VLPs containing H1 and H3 HAs induced neutralizing activities against the homologous and closely related H1N1 strains A/PR/8/34 and A/WSN/33 as well as the H3N2 strains A/Aichi/ 2/68 and A/Hong Kong/68, but not the A/Philippines/2/82 strain isolated 14 years later. HA sequence and structure analysis indicated that antigenic distance could be a major factor in predicting cross-protection by VLP vaccines. The bivalent influenza VLP vaccine demonstrated advantages in broadening the protective immunity after lethal challenge infections when compared to a monovalent influenza VLP vaccine. High levels of the inflammatory cytokine IL-6 were observed in naïve or unprotected immunized mice but not in protected mice upon lethal challenge. These results indicate that multivalent influenza VLP vaccines can be an effective strategy for developing safe and alternative vaccine to control the spread of influenza viruses.

show abstract

“…In recent years, virus-like particles (VLPs), which are formed upon recombinant expression of the viral matrix and/or surface glycoproteins, have been recognized as representing powerful tools for developing novel vaccines and investigating certain aspects of the viral replication cycle (24,44,59,63). Matrix proteins from many enveloped RNA viruses, including retroviruses, rhabdoviruses, filoviruses, paramyxoviruses, orthomyxoviruses, and arenaviruses, are able to induce VLPs (10, 14, 18, 28-30, 48, 49, 52).…”

mentioning

confidence: 99%